Related Experiment Video
Updated: Aug 13, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Growth hormone therapy update in Thailand
K Angsusingha1, S Watcharasindhu, S Likitmaskul
1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Insights
Recombinant DNA human growth hormone (rhGH) therapy significantly improved height velocity in children with growth hormone deficiency (GHD) in Thailand. The treatment showed no adverse effects, indicating its safety and efficacy for pediatric GHD management.
Area of Science:
- Pediatrics
- Endocrinology
- Growth Disorders
Background:
- Growth hormone deficiency (GHD) affects numerous children globally.
- Idiopathic isolated GHD is a common diagnosis among pediatric patients.
- Limited access to recombinant DNA human growth hormone (rhGH) treatment in Thailand was observed.
Purpose of the Study:
- To evaluate the efficacy and safety of rhGH therapy in Thai children with GHD.
- To assess the impact of rhGH on height velocity and height standard deviation score (SDS).
Main Methods:
- A cohort of 30 GHD children received rhGH treatment for 1-2 years.
- Height velocity, bone age, and height SDS were monitored.
- Thyroid function and glycosylated hemoglobin levels were assessed.
Main Results:
- Statistically significant increases in height velocity were observed post-treatment (8.17+/-1.9 cm/year and 7.36+/-2.8 cm/year at 1 and 2 years, respectively) compared to pretreatment values (3.91+/-1.09 cm/year).
- Improved height SDS was noted at the end of each treatment period.
- No adverse effects or abnormalities in thyroid function or glycosylated hemoglobin were reported.
Conclusions:
- rhGH therapy is effective in improving linear growth in Thai children with GHD.
- The treatment is well-tolerated with a favorable safety profile.
- rhGH therapy offers a viable therapeutic option for pediatric GHD in the studied population.
Abstract:
There were 841 children in Thailand with growth hormone deficiency (GHD) from January 1992 to 1996. Idiopathic isolated GHD was the major diagnosis. Only 40.19% received recombinant DNA human growth hormone (rhGH) treatment. Also reported here is a 1-2 year study of rhGH therapy in 30 GH-deficient children (21 males, 9 females), aged (mean +/- SD) 10.41+/-3.16 years, and bone age 7.37+/-3.34 years. The height velocity 1 and 2 years posttreatment were 8.17+/-1.9 and 7.36+/-2.8 cm/year respectively, which were statistically significant compared to pretreatment values of 3.91+/-1.09 cm/ year. Improved height SDS was observed at the end of each treatment period. Thyroid function and glycosylated hemoglobin tests were normal during the treatment period. There were no reports of side effects.
Related Concept Videos
Nature and Nurture
Gene Therapy
Satellite Stem Cells and Muscular Dystrophy
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon
Healing I: Introduction

